Newly designed higher affinity monoclonal antibody for cancer treatment

Recently, Prof. XIE Can from the High Magnetic Field Laboratory of the Hefei Institutes of Physical Science (HFIPS), in a collaboration with Prof. YAN Xiyun's lab from the Institute of Biophysics, reported the structural basis of mAb AA98's inhibition on CD146-mediated endothelial cells (EC) activation and designed higher affinity monoclonal antibody HA98 for cancer treatment.

Monoclonal Antibodies

Monoclonal Antibodies. Image Credit: ustas7777777/Shutterstock.com

CD146 is an adhesion molecule that plays important role in angiogenesis, cancer metastasis, and immune response. Prof. YAN Xiyun's lab has been focused on the function of CD146 and the mechanism underlay, aiming to develop antibody drugs targeting CD146.

Their previous studies demonstrated that CD146 triggered the signaling cascade via dimerization induced by various ligands. AA98, a monoclonal antibody (mAb) binding to CD146, shows inhibitory effects on tumor growth. However, the structural basis of CD146 activation and AA98 inhibition remains to be addressed.

In this research, the researchers described a crystal structure of the CD146/AA98 Fab complex at a resolution of 2.8 angstroms. Structural analysis elucidated AA98 stabilized CD146 in monomer conformation thus inhibited EC activation. A higher-affinity AA98 variant (named HA98) was then rationally designed based on the complex structure in this study.

Further experiments on an animal model with HA98 revealed superior inhibitory effects on tumor growth to those of AA98, which suggested future applications of this antibody in cancer therapy.

There was so much to do, this collaborative project was initiated about 9 years ago. The crystal structure of CD146/AA98 complex was only the first step, and how to use the structural information we obtained in rational design was much more attractive to us. Researchers from two labs have been working together from different perspectives to bring up a better antibody for potential cancer therapy. The collaboration was successful indeed."

XIE Can, Professor, High Magnetic Field Laboratory, Hefei Institutes of Physical Science (HFIPS)

Source:
Journal reference:

Chen, X., et al. (2021) Structure basis for AA98 inhibition on the activation of endothelial cells mediated by CD146. iScience. doi.org/10.1016/j.isci.2021.102417.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
One-Third of Antibody Drugs Show Unintended Target Binding